Nature Biotechnology 35,103 (2017) doi:10.1038/nbt0217-103b Published online 08 February 2017
The Shire deal includes preclinical drug programs in cystic fibrosis and urea cycle disorders to augment RaNa’s pipeline. In 2015, RaNa raised $55 million in venture capital to continue development of epigenetic gene upregulation and mRNA stabilization technologies and support the company’s programs in spinal muscular dystrophy and Friedreich’s ataxia.
Thursday, February 9, 2017
Subscribe to:
Posts (Atom)
